Sun Pharmaceutical Industries Share Price

Sun Pharmaceutical Industries Ltd is the world’s fourth-largest specialty generic pharmaceutical company. With a network of over 40 manufacturing facilities, the company distributes medicines to more than over 100 countries worldwide. The company has a global employee base of over 41,000.

The company’s recent acquisition of Concert Pharmaceuticals Inc in the United States has granted it access to the late-stage asset deuruxolitinib, which has completed Phase-3 studies for treating alopecia areata. Founded in 1983, Sun Pharma has a market capitalisation of ₹2,98,705 crore as of December 19, 2023. Sun Pharma share price has gained 114% in the last 3 years.

Business portfolio

The company manufactures and markets a wide range of pharmaceutical formulations, which include generics, branded generics, over-the-counter, antiretrovirals, intermediates and active pharmaceutical ingredients. In specialty medications, Sun Pharma has a portfolio of patent-protected drugs. With focus on dermatology, ophthalmology and oncology, the company aims to improve patient outcomes by addressing unmet medical needs and enhancing convenience through diverse dosage forms.

Sun Pharma provides high-quality generic and branded medicines to patients and healthcare professionals in over 100 countries. These medicines are available in tablets, capsules, injectables, inhalers, ointments, creams and liquids.

The therapeutic segments covered by the company’s portfolio includes psychiatry, anti-infectives, neurology, cardiology, orthopaedics, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Sun Pharma consistently ranks among the leading companies in these therapy areas. Presently, it’s one of the top companies in the United States, having introduced a number of speciality items.

When it comes to over-the-counter medications, Sun Pharma’s range is diverse. Its flagship OTC brands such as Faringosept (sore throat), Revital (vitamins) and Volini (topical analgesics) are available globally.

With regards to active pharmaceutical ingredients (APIs), Sun Pharma began producing them in 1995. The company manufactures more than 300 APIs that are sold in over 60 countries. These are manufactured in 14 sites spread across India, Hungary, the United States, Israel and Australia.

Sun Pharma provides a selection of antiretroviral (ARV) drugs that have been prequalified by the WHO. The company works with groups like the Clinton Health Access Initiative (CHAI) to lower the cost of triple medication combinations and provides ARVs to various National AIDS treatment programmes in Africa.

Bioequivalent ARV medications and APIs are produced at WHO-prequalified facilities in India, a PIC/S-approved facility in South Africa and a plant in Russia, all of which are part of Sun Pharma’s portfolio.

Financial highlights

In FY23, the total income of the company stood at ₹44,520 crore, compared to ₹39,576 crore in the previous fiscal year. The company’s net profit after minority interest for FY23 was ₹8,473.6 crore, compared to ₹3,272.7 crore in FY22. Its earnings per share (EPS) for FY23 stood at ₹35.3, compared to ₹13.6 in FY22. The company made a capital expenditure of ₹60 crore in FY23 as against ₹87 crore in FY22. The research and development (R&D) expenditure stood at ₹2,367.6 crore in FY23.

07 September 2025 – Sun Pharmaceutical Industries Share Price Update

As of last trading day, Sun Pharmaceutical Industries opened at ₹1,582.40 and last traded at ₹1,593.60, showing a rise of 11.30 points (0.71%) compared to the previous close of ₹1,582.30. During the session, the stock touched a high of ₹1,599.30 and a low of ₹1,575.50. The company's market capitalization now stands at ₹3,82,358 Crs, with a P/E ratio of 37.2 and a dividend yield of 0.92%.